Some Cancer Drugs Without Proven Benefit Still Recommended
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval
Lung Cancer
Increase in Global Incidence of Mesothelioma From 1990 to 2017
Mesothelioma incident cases and deaths associated with mesothelioma decreased after 20 years of complete ban on asbestos
Atezolizumab Gets Priority Review as Adjuvant Treatment for Early NSCLC
The sBLA is supported by data from the IMpower010 study that compared atezolizumab with best supportive care in 1005 adults with Stage IB-IIIA NSCLC after resection and adjuvant chemotherapy.
Presence of Particulate Prompts Recall of Topotecan Injection
To date, Teva has not received any further complaints or adverse events reports related to this recall.
Lumakras Gets Accelerated Approval for KRAS G12C-Mutated NSCLC
The Food and Drug Administration (FDA) has granted accelerated approval to Lumakras (sotorasib) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least 1 prior systemic therapy. Sotorasib, an inhibitor of the RAS GTPase family, works by…
Rybrevant Approved for NSCLC With EGFR Exon 20 Insertion Mutations
The approval was based on data from the phase 1 CHRYSALIS trial that evaluated Rybrevant in 81 patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease had progressed on or after platinum-based chemotherapy.
Worse Pulmonary Function Associated With Lower Survival Rates in Lung Cancer
Patients with lung cancer and poor pulmonary function at diagnosis have worse rates of overall survival.
Mobocertinib Gets Priority Review for EGFR Exon20 Insertion+ Metastatic NSCLC
Mobocertinib is an investigational, first-in-class, oral tyrosine kinase inhibitor designed to selectively target EGFR Exon20 insertion mutations.
Indications Withdrawn as FDA Evaluates Several Accelerated Approvals
To prove clinical benefit, the FDA requires manufacturers to conduct confirmatory trials, also known as a phase 4 studies.
USPSTF Expands Eligibility for Annual Lung Cancer Screening
Adults aged 50 to 80 years with 20 pack-year smoking history who currently smoke or quit within last 15 years should be screened with low-dose CT
